Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132653 | 0.89 | KDM4E (0.40) | KDM4EDAOHTR2AHTR2CHTR2B | |
| SCHEMBL17145132 | 0.89 | KDM4E (0.40) | KDM4EDAOHTR2AHTR2CHTR2B | |
| SCHEMBL883075 | 0.79 | KDM4E (0.35) | HSD17B10KDM4EALDH1A1LMNAHTT | |
| SCHEMBL10286519 | 0.78 | BRD4 (0.34) | HSD17B10KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL10271346 | 0.78 | S100A4 (0.34) | HSD17B10KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL10286174 | 0.76 | NOS3 (0.36) | HSD17B10KDM4EALDH1A1LMNAHTR2A | |
| SCHEMBL23783013 | 0.75 | ALDH1A1 (0.34) | HSD17B10KDM4EALDH1A1MAPTSPR | |
| SCHEMBL10286507 | 0.75 | GABRG2 (0.36) | HSD17B10KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL10286197 | 0.74 | NOS3 (0.43) | PARP1NOS3NOS1NOS2 | |
| SCHEMBL10286114 | 0.74 | BCL2L1 (0.37) | HSD17B10KDM4EALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652168-A1 | 5-AMINO-1H-PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340554-A1 | 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 | BEONE MEDICINES I GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2025068985-A1 | 1-(1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024153230-A1 | 5-AMINO-1H-PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE, LTD. (KY) | 2024-07-25 | — | — | WO | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013139822-A1 | NOVEL BISOXIME MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| EP-2641901-A1 | Novel microbiocides | Syngenta Participations AG. (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013092460-A1 | CYCLIC BISOXIME MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012013754-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | HSD17B10 1909/4885KDM4E 3618/4885ALDH1A1 1154/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | HSD17B10 2290/4885KDM4E 1075/4885ALDH1A1 1110/4885 |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | PRDX4, PRDX6, DDT | HSD17B10 2498/4885KDM4E 428/4885ALDH1A1 1961/4885 |
| US-20250340554-A1 | 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 | PRMT5, PRMT1, PRMT3 | HSD17B10 4590/4885KDM4E 59/4885ALDH1A1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.